Failing, getting stuck and plain being wrong happen in science all the time By February, the suspense was too much. Again the Wall Street Journal, following the bouncing dollar, reported that Bristol-Myers, which has the rights to develop angiostatin, was shelving the product for the time being. An official at EntreMed, a small biotech company which also has an interest in angiostatin and endostatin (see Gazetteer, Curr Biol 1998, 8 8: :R633) , tried to convince the New York Times that the Bristol-Myers announcement was a "non-event". But investors didn't buy that; the price of an EntreMed share dropped 47% in a single day.
Folkman himself by and large has avoided the media. But in February, a reporter from the Boston Herald sat in on a talk he gave in Boston. "Folkman said one reason other labs, including NCI, have had problems reproducing his work is that it is difficult to learn how to inject the mice with the drug without killing them. 'It takes a lot of skill to not lose a mouse,' he said. 'We spend a lot of time teaching them how to do it'." One could argue whether this comment helped resolve the mystery, or simply added to it. National Public Radio devoted an entire story to the process of science, using the angiostatin affair as a stepping-off point. "Scientists have learned to be skeptics," reported Alison Richards. "They know that however convincing a new piece of research is, problems will arise. Failing, getting stuck and plain being wrong happen in science all the time, but you don't usually hear about it, unless, of course, you read the science journals."
The Boston Globe, in turn, broke some encouraging news in mid-February. NCI scientists, working in Folkman's lab, had finally been able to reproduce his results. " 'This substantiates the idea that these are technical issues' that caused the initial failures of the drug to work at the institute," NCI's Robert Wittes told the Boston Globe. "Now we will move to facilities in Frederick and try to reproduce the results down here." But while reporting that EntreMed's stock value doubled on that news, the Wall Street Journal didn't breathe a final sigh of relief. "Independent confirmation of Folkman would be very exciting; however, these results don't qualify as such," George Yancopoulos, chief scientific officer at Regeneron Pharmaceuticals, told the Journal. "What worries me is that several years after the discovery of endostatin, there is still no explanation for how it works. It's still black magic." Wittes at the NCI added his note of caution: "We have to make sure it's synthesizable outside Boston."
